The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...
Everyday Health on MSN
Why histological healing is the new benchmark for your ulcerative colitis
For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new ...
Everyday Health on MSN
How to manage a career and family during an ulcerative colitis treatment switch
Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...
Bethesda, MD (Nov. 15, 2024) — The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, ...
Ulcerative colitis (UC) is a chronic, immune-mediated inflammatory disorder of the colon that follows a relapsing-remitting course. Characterised by mucosal inflammation, the disease requires accurate ...
Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
T he goal of ulcerative colitis (UC) treatment is twofold: to heal the inflamed mucosal lining of the gut and to eliminate symptoms such as cramping and pain (usually once the inflammation subsides).
Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results